http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011140807-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-7233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2878 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2010-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011140807-A |
| titleOfInvention | METHOD FOR DETECTING DEGENERATIVE MUSCULAR DISEASES AND METHOD FOR DETERMINING THERAPEUTIC EFFICIENCY FOR DISEASES |
| abstract | 1. A method for detecting a muscular degenerative disease, wherein the method comprises the step of measuring the content of tetranor-PGDM in a sample isolated from an individual. A method for determining the effectiveness of a therapeutic agent and / or a method for treating a muscular degenerative disease, wherein the method comprises the step of measuring the content of tetranor-PGDM in a sample isolated from a patient with a muscular degenerative disease. 3. The method of claim 1 or 2, wherein the sample is urine. The method of claim 1 or 2, wherein tetranor-PGDM is determined by high performance liquid chromatography in combination with tandem mass spectrometry (HPLC-MS / MS), enzyme immunoassay (EIA), radioimmunoassay (RIA), fluorescence immunoassay (FIA) enzyme-linked immunosorbent assay (ELISA) or enzymatic method. 5. The method of claim 1 or 2, wherein the muscular degenerative disease is progressive muscular dystrophy, hereditary muscular dystrophy, pelvic-brachial muscular dystrophy, shoulder-scapular-facial muscular dystrophy, myotonic muscular dystrophy, amyotrophic lateral sclerosis or myopathy. A kit for the diagnostic determination of muscle degenerative disease, where the kit contains an antibody to tetranor-PGDM. 7. A kit for predicting and / or determining the effectiveness of a therapeutic agent and / or a method for treating muscular degenerative disease, wherein the kit contains an anti-tetranor-PGDM antibody. 8. A kit according to claim 6 or 7, comprising antibodies to tetranor-PGDM, labeled tetranor-PGDM and optionally at least one compound selected from the group consisting of antibodies to immunoglob� |
| priorityDate | 2009-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44600448 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423280275 |
Total number of triples: 18.